Medication info
Gavsmate Tablet 50/1000 Milligrams

Gavsmate Tablet 50/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Novartis Korea Ltd.
Appearance
Dark yellow oval film-coated tablet
Packaging
60 tablets (10 tablets in PTP packaging x 6)
Approval status
Active

MFDS item code 200803517 · Approved 2008.03.31 · Insurance code 653601430

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin of 100mg or more per day are not recommended. This medication should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received pharmacological treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose of this medication is 50/500mg, taken as 1 tablet once daily. The dose may be gradually increased to 50/1000mg, taken as 1 tablet twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should provide 100mg of vildagliptin per day and the patient's existing dose of metformin. The initial dose of this medication should be determined according to the patient's current treatment regimen. Take 1 tablet of this medication 50mg/850mg or 50mg/1000mg in the morning and evening, twice daily. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medication may start at their existing doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the patient's existing dose. - When this medication is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medication, take it with the next meal unless it is time for your next dose. Do not take a double dose at one time to make up for the missed dose. Patients with hepatic impairment This medication is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medication.

Ingredients

Importer
Novartis Korea Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to help patients with type 2 diabetes control their blood sugar by using vildagliptin and metformin together. It helps improve blood sugar management effectively when used along with dietary therapy and exercise therapy. This helps stabilize blood sugar levels and facilitates better management of diabetes. This medication is used for the treatment of type 2 diabetes.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medication should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin of 100mg or more per day are not recommended. This medication should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received pharmacological treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose of this medication is 50/500mg, taken as 1 tablet once daily. The dose may be gradually increased to 50/1000mg, taken as 1 tablet twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should provide 100mg of vildagliptin per day and the patient's existing dose of metformin. The initial dose of this medication should be determined according to the patient's current treatment regimen. Take 1 tablet of this medication 50mg/850mg or 50mg/1000mg in the morning and evening, twice daily. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medication may start at their existing doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the patient's existing dose. - When this medication is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medication, take it with the next meal unless it is time for your next dose. Do not take a double dose at one time to make up for the missed dose. Patients with hepatic impairment This medication is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal, before starting treatment with this medication.

Precautions

This medication is a drug that helps control blood sugar. However, it should not be administered to patients with poor kidney function, heart disease, severe infections, or those facing major surgery. This medication can cause a serious side effect called lactic acidosis, which is a dangerous condition where lactic acid accumulates excessively in the body. If symptoms are suspected, it is essential to notify the healthcare provider immediately. Additionally, it is not recommended to use this medication in patients with liver dysfunction or those who consume excessive alcohol. Pregnant or breastfeeding women should also avoid taking this medication. During the course of this medication, attention should be paid to hypoglycemic symptoms, especially when skipping meals or engaging in vigorous exercise. There may be drug interactions, so if you are taking other medications, please inform your doctor or pharmacist. Elderly patients should regularly undergo kidney function tests as kidney function may decline, and dosage adjustments may be necessary. Regular blood tests and liver function tests are important to monitor health during this medication. If symptoms of acute pancreatitis appear, stop taking the medication immediately and visit the hospital. This medication is not recommended for children or adolescents under 18. In case of overdose, visit the hospital immediately for appropriate treatment. This medication can be removed by hemodialysis, so follow the instructions of the healthcare provider. Store this medication out of reach of children, and it is advisable not to transfer it to another container. Lastly, if abnormal symptoms like blisters or ulcers appear on the skin during the treatment with this medication, consult a doctor immediately.

Side effects

Lactic acidosis, hypoglycemia, hepatitis, impaired liver function, increased transaminase levels, angioedema, tremors, headache, dizziness, fatigue, nausea, gastroesophageal reflux, diarrhea, bloating, chills, decreased blood sugar, weakness, sweating, constipation, arthralgia, upper respiratory infection, rhinitis, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, decreased appetite, taste disturbance, skin reactions (erythema, itching, urticaria), pancreatitis, hives, blisters, exfoliative skin lesions, severe and debilitating arthralgia, cutaneous vasculitis, cholecystitis, dyspepsia, abdominal discomfort, gastrointestinal abnormalities, increased serum amylase, increased lipase, vesicular pemphigoid, myalgia, paresthesia, fever, swelling, swelling of hands and feet, increased creatine phosphokinase, elevated AST, increased C-reactive protein, elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. It is also important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Dark yellow oval film-coated tablet

Package unit

60 tablets (10 tablets in PTP packaging x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.